Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Bristol-Myers Squibb Company reported revenue of $48.19B, down 0.2% year over year. Operating margin was 19.4% and net margin 14.6%, on a free-cash-flow margin of 26.7% with capital expenditure at 2.7% of revenue. Every figure is computed directly from BMY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $48.19B | 19.4% | 14.6% |
| FY2024 | $48.30B | -17.3% | -18.5% |
| FY2023 | $45.01B | 18.8% | 17.8% |
| FY2022 | $46.16B | 16.7% | 13.7% |
| FY2021 | $46.38B | 17.5% | 15.1% |
How does BMY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.